

**MAP3K13 (LZK) Antibody (C-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP8008a****Specification**

---

**MAP3K13 (LZK) Antibody (C-term) Blocking peptide - Product Information**Primary Accession [O43283](#)**MAP3K13 (LZK) Antibody (C-term) Blocking peptide - Additional Information****Gene ID** 9175**Other Names**

Mitogen-activated protein kinase kinase kinase 13, Leucine zipper-bearing kinase, Mixed lineage kinase, MLK, MAP3K13 ([http://www.genenames.org/cgi-bin/gene\\_symbol\\_report?hgnc\\_id=6852](http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=6852))  
HGNC:6852

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP8008a](/product/products/AP8008a) was selected from the C-term region of human LZK. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**MAP3K13 (LZK) Antibody (C-term) Blocking peptide - Protein Information****Name** MAP3K13 ([HGNC:6852](#))**Function**

Activates the JUN N-terminal pathway through activation of the MAP kinase kinase MAP2K7. Acts synergistically with PRDX3 to regulate the activation of NF-kappa-B in the cytosol. This activation is kinase-dependent and involves activating the IKK complex, the IKBKB-containing complex that phosphorylates inhibitors of NF-kappa-B.

**Cellular Location**

Cytoplasm. Membrane; Peripheral membrane protein

**Tissue Location**

Expressed in the adult brain, liver, placenta and pancreas, with expression strongest in the pancreas

### **MAP3K13 (LZK) Antibody (C-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

### **MAP3K13 (LZK) Antibody (C-term) Blocking peptide - Images**

### **MAP3K13 (LZK) Antibody (C-term) Blocking peptide - Background**

Protein kinases are enzymes that transfer a phosphate group from a phosphate donor, generally the  $\gamma$  phosphate of ATP, onto an acceptor amino acid in a substrate protein. By this basic mechanism, protein kinases mediate most of the signal transduction in eukaryotic cells, regulating cellular metabolism, transcription, cell cycle progression, cytoskeletal rearrangement and cell movement, apoptosis, and differentiation. With more than 500 gene products, the protein kinase family is one of the largest families of proteins in eukaryotes. The family has been classified in 8 major groups based on sequence comparison of their tyrosine (PTK) or serine/threonine (STK) kinase catalytic domains. The tyrosine-like kinase (TLK) group consists of 40 tyrosine and serine-threonine kinases such as MLK (mixed-lineage kinase), LSK (LIMK/TESK), IRAK (interleukin-1 receptor-associated kinase), Raf, RIPK (receptor-interacting protein kinase), and STRK (activin and TGF-beta receptors) families.

### **MAP3K13 (LZK) Antibody (C-term) Blocking peptide - References**

Blume-Jensen P, et al. Nature 2001. 411: 355. Cantrell D, J. Cell Sci. 2001. 114: 1439. Jhian S. Oncogene 2000. 19: 5590. Manning G, et al. Science 2002. 298: 1912. Moller, D, et al. Am. J. Physiol. 1994. 266: C351-C359. Robertson, S. et al. Trends Genet. 2000. 16: 368. Robinson D, et al. Oncogene 2000. 19: 5548. Van der Ven, P, et al. Hum. Molec. Genet. 1993. 2: 1889. Vanhaesebroeck, B, et al. Biochem. J. 2000. 346: 561. Van Weering D, et al. Recent Results Cancer Res. 1998. 154: 271.